Double lethal effects of fusion gene of wild-type p53 and JunB on hepatocellular carcinoma cells

Abstract

This study explored the double lethal effects of pEGFP-C1-wtp53/junB fusion gene on hepatocellular carcinoma (HCC) cells. wtp53/junB fusion gene was constructed and transformed into HepG2 cell line. Expression of KAI1 was detected by quantitative real-time PCR and Western blotting, cells apoptosis rate was detected by flow cytometry, proliferation of cells was detected by MTT chromometry, cell transmigration was detected by using transwell systems. The results showed that after transformation with pEGFP-C1-wtp53/JunB, the expression level of KAI1 protein was up-regulated, being 8.13 times the blank control group in HepG2 cells and significantly higher than 2.87 times which transformed with pEGFP-C1-JunB, 3.11 times which transformed with pEGFP-C1-wtp53 (P<0.001). Apoptosis rate of HepG2 cells transformed with pEGFP-C1-wtp53/JunB was significantly higher than that of other groups (P<0.001), and invasive ability of HepG2 cells transformed with pEGFP-C1-wtp53/JunB was significantly lower than other groups (P<0.001). It was concluded that the fusion gene of wtp53 and JunB could not only inhibit the growth of hepatoma cells and promote tumor cell apoptosis, but also suppress the invasive ability of tumor cells by up-regulating the expression of KAI1.

Keywords

hepatocellular carcinoma / KAI1 / CD82 / p53 / JunB

References

[1] GaiX.D., LiG.L., HuangJ.Z., et al.. Reversal of multidrug resistance of human hepatocellular carcinoma cells by wild-type p53 gene and related mechanisms. Ai Zheng, 2006, 25(8): 954-959

[2] GurzovE.N., BakiriL., AlfaroJ.M., et al.. Targeting c-Jun and JunB proteins as potential anticancer cell therapy. Oncogene, 2008, 27(5): 641-652

[3] PuslT., VennegeertsT., WimmerR., et al.. Tauroursode-oxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1. Biochem Biophys Res Commun, 2008, 367(1): 208-212

[4] da Costa Reis Monte-MórB., PloI., da CunhaA.F., et al.. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage. Leukemia, 2009, 23(1): 144-152

[5] SonY.O., HeoJ.S., KimT.G., et al.. Over-expression of JunB inhibits mitochondrial stress and cytotoxicity in hu-man lymphoma cells exposed to chronic oxidative stress. BMB Rep, 2010, 43(1): 57-61

[6] MarreirosA., CzolijR., YardleyG., et al.. Identifica-tion of regulatory regions within the KAI1 promoter: a role for binding of AP1, AP2 and p53. Gene, 2003, 302(1–2): 155-164

[7] GuoC., LiuQ.G., ZhangL., et al.. Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2009, 8(4): 389-396

[8] GuoC., ZhangL., LiuQ.G., et al.. Construction of eukaryotic expression vector of wtp53/junB fusion gene. J Xi’an Jiaotong Univ (Med Sci), 2010, 31(1): 47-52

[9] PucaR., NardinocchiL., BossiG., et al.. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modu-lating metallothionein and zinc. Exp Cell Res, 2009, 315(1): 67-75

[10] BoldrupL., BourdonJ.C., CoatesP.J., et al.. Expres-sion of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer, 2007, 43(3): 617-623

[11] AndrechtS., KolbusA., HartensteinB., et al.. Cell cycle promoting activity of JunB through cyclin A activa-tion. J Biol Chem, 2002, 277(39): 35961-35968

[12] Mechta-GrigoriouF., GeraldD., et al.. The mammalian Jun proteins: redundancy and specificity. Oncogene, 2001, 20(19): 2378-2389

[13] ShaulianE., KarinM.. AP-1 in cell proliferation and survival. Oncogene, 2001, 20(19): 2390-2400

[14] ShaulianE., KarinM.. AP-1 as a regulator of cell life and death. Nat Cell Biol, 2002, 4(5): E131-136

[15] JochumW., PasseguéE., WagnerE.F.. AP-1 in mouse development and tumorigenesis. Oncogene, 2001, 20(19): 2401-2412

[16] van DH, CastellazziM.. Distinct roles of Jun Fos and Jun atf dimers in oncogenesis. Oncogene, 2001, 20(19): 2453-2464

[17] PasseguéE., WagnerE.F.. JunB suppresses cell pro-liferation by transcriptional activation of p16(INK4a) ex-pression. EMBO J, 2000, 19(12): 2969-2979

[18] ChangY.S., YehK.T., YangM.Y., et al.. Abnormal expression of JUNB gene in hepatocellular carcinoma. Oncol Rep, 2005, 13(3): 433-438

[19] DongJ.T., LambP.W., Rinker-SchaefferC.W., et al.. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science, 1995, 268(5212): 884-886

[20] DongJ.T., SuzukiH., PinS.S., et al.. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res, 1996, 56(19): 4387-4390

[21] YuY., YangJ.L., MarkovicB., et al.. Loss of KAI1 messenger RNA expression in both high-grade and inva-sive human bladder cancers. Clin Cancer Res, 1997, 3(7): 1045-1049

[22] YangX., WelchD.R., PhillipsK.K., et al.. KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett, 1997, 119(2): 149-155

[23] LombardiD.P., GeradtsJ., FoleyJ.F., et al.. Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res, 1999, 59(22): 5724-5731

[24] FriessH., GuoX.Z., BerberatP., et al.. Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer, 1998, 79(4): 349-355

[25] YangJ.M., PengZ.H., SiS.H., et al.. KAI1 gene sup-presses invasion and metastasis of hepatocellular carci-noma MHCC97-H cells in vitro and in animal models. Liver Int, 2008, 28(1): 132-139

[26] AdachiM., TakiT., IekiY., et al.. Correlation of KAI1/CD82 gene expression with good prognosis in pa-tients with non-small cell lung cancer. Cancer Res, 1996, 56(8): 1751-1755

[27] AdachiM., TakiT., KonishiT., et al.. Novel staging protocol for non-small-cell lung cancers according to MRP-1/ CD9 and KAI1/CD82 gene expression. J Clin Oncol, 1998, 16(4): 1397-1406

[28] ShoM., AdachiM., TakiT., et al.. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer, 1998, 79(5): 509-516

[29] FarhadiehR.D., SmeeR., OwK., et al.. Down-regulation of KAI1/CD82 protein expression in oral cancer correlates with reduced disease free survival and overall patient survival. Cancer Lett, 2004, 213(1): 91-98

[30] MashimoT., WatabeM., HirotaS., et al.. The expres-sion of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA, 1998, 95(19): 11307-11311

[31] MarreirosA., DudgeonK., DaoV., et al.. KAI1 pro-moter activity is dependent on p53, junB and AP2: evi-dence for a possible mechanism underlying loss of KAI1 expression in cancer cells. Oncogene, 2005, 24(4): 637-649